Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg)
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Guillain-Barre Syndrome
Conditions
Guillain-Barre Syndrome
Trial Timeline
Sep 10, 2024 → Feb 20, 2026
NCT ID
NCT05701189About Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg)
Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg) is a phase 2 stage product being developed by Argenx for Guillain-Barre Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05701189. Target conditions include Guillain-Barre Syndrome.
What happened to similar drugs?
0 of 2 similar drugs in Guillain-Barre Syndrome were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05701189 | Phase 2 | Withdrawn |
Competing Products
2 competing products in Guillain-Barre Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ANX005 + Placebo | Annexon | Phase 3 | 34 |
| Tanruprubart | Annexon | Phase 3 | 41 |